

Special Issue

Clinical Advances and Therapeutic Challenges in Small-Cell Lung Cancer and Rare Thoracic Cancers

Message from the Guest Editor

The clinical decision-making process for patients with rare tumors poses a significant challenge in oncology, particularly in defining individualized therapeutic strategies. Unlike common malignancies, the available evidence and literature on rare tumors are predominantly limited to case series, retrospective studies, and small phase II prospective trials. Randomized trials, which are usually the cornerstone of therapeutic paradigms, are frequently unavailable or constrained by a limited sample size and the heterogeneity of enrolled populations. Given this context, therapeutic decisions are largely based on physicians' experience, guidelines developed by expert panels, and extrapolations from available evidence derived from different disease settings. This Special Issue is dedicated to small-cell lung cancer and rare thoracic tumors, with a particular focus on epithelial thymic tumors, thoracic neuroendocrine neoplasms, and pleural mesothelioma. I look forward to receiving your contributions.

Guest Editor

Prof. Dr. Tommaso Martino De Pas

Department of Medical Oncology, Cliniche Humanitas Gavazzeni,
24125 Bergamo, Italy

Deadline for manuscript submissions

20 March 2026



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/241448

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncol](https://mdpi.com/journal/currentoncol)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currenocol](https://mdpi.com/journal/currenocol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)